CAS 2023788-19-2 is a novel dual receptor agonist of glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic peptide (GIP, also known as gastric inhibitory peptide), administered once a week. GLP-1 and GIP both belong to enterotropin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing hypoglycemic effects. It can also delay gastric emptying and inhibit appetite, thereby controlling weight; The latter has functions such as inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the action of GLP-1 receptor agonists. Tirzepatide integrates two insulin promoting effects into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.
This molecule consists of a peptide backbone of 39 amino acids and a side chain at the residue Lys20. Out of 39 amino acids, 37 are naturally present (or encoded), and two are non naturally present, with non coding amino isobutyric acid residues located at positions 2 and 13.
TirzepatideCAS 2023788-19-2 has a similar sequence to semaglutide, and the lys side chain in the sequence is modified with PEG, which is a functional group of peptides and can increase the water solubility of the sequence. The main physiological function of Tirzepatide is glucose dependent insulin nutritional polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.
The SURPASS study is a series of large randomized controlled clinical trials aimed at evaluating the efficacy and safety of tilporide in patients with type 2 diabetes mellitus (T2DM). Among them, the results of SURPASS-2 [1] were the most encouraging when compared head-on with smeglutide. This study compared the hypoglycemic effects of tirposide 5mg (n=470), 10mg (n=469), and 15mg (n=469) with smeglutide 1mg (n=468). The results showed that compared to baseline HbA1c (8.3%) levels, telposide reduced subjects' HbA1c by an average of 2.0%, 2.2%, and 2.3%, while smeglutide decreased by an average of 1.9%; In terms of weight loss, compared to the baseline weight in the Chemicalbook (207 pounds), telposide resulted in an average weight loss of 17 pounds, 21 pounds, and 25 pounds for participants, while smeglutide was 13 pounds. This experiment showed that telposide exhibited superior hypoglycemic and weight loss abilities compared to smeglutide. Another large study recruited 2539 adults with at least one obesity complication (excluding diabetes), body mass index (BMI) Greater than or equal to 30kg/m2 or Greater than or equal to 27kg/m2. All participants were randomly divided into equal proportions into telposide 5mg, 10mg, 15mg and placebo groups. The results showed that at 72 weeks, the weight of each group decreased by 16.1kg, 22.2kg, 23.6kg, and 2.4kg, respectively. The weight loss effect of tirposide is comparable to that of weight loss surgery.
Telpolotide has a similar sequence to semaglutide, with the lys side chains in the sequence modified with PEG, which are functional groups of peptides and can increase the water solubility of the sequence. Tilpodide, which is mainly used to produce chemobooks, is a double agonist of glucose dependent insulin nutritional polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor. It is being developed for the treatment of type 2 diabetes and has entered the clinical stage.
TirzepatideCAS 2023788-19-2 is a dual agonist of glucose dependent insulinotropic peptide (GIP) receptors and glucagon like peptide-1 (GLP-1) receptors, capable of synergizing appetite, calorie intake, and metabolic function.
For example, our bodies are like a precision factory, and GIP and GLP-1 are the two very capable workers in this factory.
Research has shown that telopoptide produces stable and clinically significant reductions in glycated hemoglobin and body weight, with a greater decrease than all evaluated control drugs - placebo, 1mg of sitagliptin injection, titrated insulin diglutide, and titrated insulin glargine.
Mobile: +86 -29-86107037-8012
Tel/Wechat : 18729555803